The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
- 29 March 2010
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 5 (4), 305-310
- https://doi.org/10.1517/17460441003677725
Abstract
The extent and duration of pharmacological action is determined by the lifetime of drug occupancy on a molecular target. This lifetime is defined by dynamic processes that control the rates of drug association and dissociation from the target. Recently, the term residence time has been coined to describe experimental measurements that can be related to the lifetime of the binary drug-target complex, and this in turn to durable, pharmacodynamic activity. The residence time concept and its impact on drug optimization are reviewed here. Examples are provided that demonstrate how a long residence time can improve drug efficacy in vivo. Additionally, optimization of drug-target residence time can help to mitigate off-target mediated toxicity, hence, improving drug safety and tolerability. Recent applications of the residence time concept to both drug discovery and development are also presented.Keywords
This publication has 25 references indexed in Scilit:
- The role of dynamic conformational ensembles in biomolecular recognitionNature Chemical Biology, 2009
- Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterolBritish Journal of Pharmacology, 2009
- Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerationsDrug Discovery Today, 2009
- Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: Application to (R)-dimethindene occupancy of central histamine H1receptorsJournal of Receptors and Signal Transduction, 2009
- Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative BehaviorBiochemistry, 2009
- Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis: Residence Time and in Vivo ActivityACS Chemical Biology, 2009
- Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic BarrierJournal of Virology, 2007
- Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo EfficacyThe Journal of pharmacology and experimental therapeutics, 2007
- Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial RibosomesAntimicrobial Agents and Chemotherapy, 2006
- Address in Pathology ON CHEMOTHERAPEUTICS:: SCIENTIFIC PRINCIPLES, METHODS, AND RESULTSThe Lancet, 1913